Tag Archives: defactinib

Scrubbed Trial May Not Be the End for Mesothelioma Drug

The makers of the once-promising experimental mesothelioma drug defactinib have announced that they will stop a clinical trial of the drug early because, by itself, it does not appear to help. But this may not be the end of the road for defactinib in mesothelioma treatment. Defactinib (VS-6063) had been the leading compound for its manufacturer, Boston-based Verastem. While standard mesothelioma chemotherapy drugs like pemetrexed, cisplatin, gemcitabine and vinorelbine can sometimes shrink mesothelioma tumors, they also increase the percentage of stem cells which can give rise to new cancer. Defactinib was designed to help keep malignant mesothelioma patients from relapsing by inhibiting a crucial signaling pathway (FAK) inside the stem cells. Early studies were encouraging, but a recent review of … Continue reading Scrubbed Trial May Not Be the End for Mesothelioma Drug »